All companies › RLAY

RLAY · Relay Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells3
Research cases0
Last filing2026-10-07

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-10-06 — Catinazzo Thomas · sold 17,511 @ $18.58 2026-10-06 — Catinazzo Thomas · sold 206 @ $19.26 2026-10-07 — Patel Sanjiv · sold 48,199 @ $18.10
2026-10-062026-10-07

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Catinazzo Thomas Chief Financial Officer
Patel Sanjiv President and CEO, Director
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $RLAY is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-07', 'insider_name': 'Patel Sanjiv', 'insider_title': 'President and CEO, Director', 'transaction_type': 'Open-market sell', 'shares': 48199.0, 'price': 18.1, 'value': 872401.9, 'is_buy': False}, {'transaction_date': '2026-10-06', 'insider_name': 'Catinazzo Thomas', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 17511.0, 'price': 18.58, 'value': 325354.38, 'is_buy': False}, {'transaction_date': '2026-10-06', 'insider_name': 'Catinazzo Thomas', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 206.0, 'price': 19.26, 'value': 3967.56, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for RLAY today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.